New Director

T cell therapy developer Crescendo Biologics Ltd (Crescendo) has named Eva-Lotta Allan Non-Executive Director of the company. The former CFO of Immunocore brings in over 30 years’ experience in the biopharmaceutical industry, with special expertise in strategic partnerships with Big Pharma. The Board member of the British Industry Organisation (BIA) is currently a non-executive director for cancer immunotherapy specialist Targovax ASA which recently announced new patents for its colon cancer RAS-targeting candidate drug TG02. Prior to Immunocore, Eva-Lotta was Chief Business Officer at Ablynx NV.